Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jorien Harting
Autologous Tumor Cell Vaccination Combined With Systemic CpG-B and IFN-α Promotes Immune Activation and Induces Clinical Responses in Patients With Metastatic Renal Cell Carcinoma: A Phase II Trial
Cancer Immunology, Immunotherapy
Cancer Research
Medicine
Oncology
Allergy
Immunology
Related publications
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination Combined With Sunitinib for Metastatic Renal Cell Carcinoma
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine With Aldesleukin (Interleukin 2) and IFN- 2a Therapy in Metastatic Renal Cell Carcinoma Patients
Clinical Cancer Research
Cancer Research
Oncology
A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients With Metastatic Renal Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Phase II Clinical Trial of Adoptive Cell Therapy for Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2
Cancer Immunology, Immunotherapy
Cancer Research
Medicine
Oncology
Allergy
Immunology
The Effect of Everolimus and Low-Dose Cyclophosphamide on Immune Cell Subsets in Patients With Metastatic Renal Cell Carcinoma: Results From a Phase I Clinical Trial
Cancer Immunology, Immunotherapy
Cancer Research
Medicine
Oncology
Allergy
Immunology
Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma
Urology
Urology
Intratumoral G100, a TLR4 Agonist, Induces Anti-Tumor Immune Responses and Tumor Regression in Patients With Merkel Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Vaccination With LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial
Clinical Cancer Research
Cancer Research
Oncology
